Role of MicroRNAs in Treatment Response in Prostate Cancer
[ Vol. 18 , Issue. 10 ]
Anshuli Razdan, Paul de Souza* and Tara Laurine RobertsPages 929-944 (16)
Prostate cancer (PCa) is the most common non-skin cancer in men worldwide, resulting in significant mortality and morbidity. Depending on the grade and stage of the cancer, patients may be given radiation therapy, hormonal therapy, or chemotherapy. However, more than half of these patients develop resistance to treatment, leading to disease progression and metastases, often with lethal consequences. MicroRNAs (miRNAs) are short, non-coding RNAs, which regulate numerous physiological as well as pathological processes, including cancer. miRNAs mediate their regulatory effect predominately by binding to the 3′-untranslated region (UTR) of their target mRNAs. In this review, we will describe the mechanisms by which miRNAs mediate resistance to radiation and drug therapy (i.e. hormone therapy and chemotherapy) in PCa, including control of apoptosis, cell growth and proliferation, autophagy, epithelial-to-mesenchymal transition (EMT), invasion and metastasis, and cancer stem cells (CSCs). Furthermore, we will discuss the utility of circulating miRNAs isolated from different body fluids of prostate cancer patients as non-invasive biomarkers of cancer detection, disease progression, and therapy response. Finally, we will shortlist the candidate miRNAs, which may have a role in drug and radioresistance, that could potentially be used as predictive biomarkers of treatment response.
MicroRNAs (miRNAs), biomarkers, prostate cancer, therapy response, radiation and drug therapy, apoptosis.
Medical Oncology Group, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Medical Oncology Group, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Medical Oncology Group, Ingham Institute for Applied Medical Research, Liverpool, New South Wales
Read Full-Text article